验证码已发送至您的邮箱或手机,请查收。
Lulizumab pegol
Phase II Active
A CD28 targeted antibody potentially for the treatment of systemic lupus erythematosus and Sjoegren's syndrome.
Research Code BMS-931699; Lulizumab
CAS No. 1421830-13-8
Onartuzumab
(MetMAb®) Phase III Discontinued
A MET blocker used to treat metastatic non-small cell lung cancer and gastric cancer.
Research Code OA-5D5; PRO-143966; RG-3638; RO-5490258
CAS No. 1133766-06-9
Friendly Links:
CFDA US FDA EMA PMDA NCBI EPO ACS Wikipedia KEGG DrugBank 生物谷
Successful modification
Please choose to cancel the drug